85. Idiopathic interstitial pneumonia
514 clinical trials,   377 drugs   (DrugBank: 108 drugs),   97 drug target genes,   204 drug target pathways
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03286556 (ClinicalTrials.gov) | September 4, 2018 | 12/9/2017 | Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis | Study of Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF) | Idiopathic Pulmonary Fibrosis, Acute Fatal Form | Drug: Autoantibody Reductive Therapy;Drug: Treatment as Usual (TAU) | University of Alabama at Birmingham | National Heart, Lung, and Blood Institute (NHLBI);Brigham and Women's Hospital;Temple University;University of Pittsburgh | Recruiting | 40 Years | 85 Years | All | 51 | Phase 2 | United States |